# Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma

> **NCT07365280** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ZSky Biotech Inc** · enrollment: 78 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **BIOLOGICAL:** Personalized Dendritic Cell Vaccine ZSNeo-DC1.1
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT07365280
- **Lead sponsor:** ZSky Biotech Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2028-12-24
- **Final completion:** 2028-12-24
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07365280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07365280, "Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07365280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*